Surrozen (SRZN) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
13 May, 2026Opening remarks and agenda
The meeting was called to order with directors, officers, employees, and auditors present via webcast or phone.
Voting procedures and meeting rules were outlined, with polls open until shortly after the meeting began.
Legal notice of the meeting was confirmed, and a quorum was established with at least one-third of outstanding shares represented.
Four agenda items were presented: election of directors, ratification of auditors, advisory vote on executive compensation, and advisory vote on compensation vote frequency.
Board and executive committee updates
Two nominees, Dr. Mace Rothenberg and Dr. David J. Woodhouse, were up for election as Class II directors to serve until the 2029 annual meeting.
Overview of voting outcomes
Both director nominees were elected to serve until the 2029 annual meeting or until successors are qualified.
Ernst & Young LLP was ratified as the independent registered public accounting firm for 2026.
Executive compensation as disclosed in the proxy statement was approved.
Stockholders preferred an annual advisory vote on executive compensation.
Final voting results will be filed with the SEC and maintained in corporate records.
Latest events from Surrozen
- Multi-functional antibodies targeting Wnt, VEGF, and IL-6 address major unmet needs in retinal disease.SRZN
Corporate presentation7 May 2026 - Net loss widened to $127.5M as cash reached $106.9M; IND for SZN-8141 on track for H2 2026.SRZN
Q1 20266 May 2026 - Annual meeting covers director elections, auditor ratification, and executive compensation votes.SRZN
Proxy filing1 Apr 2026 - Virtual annual meeting to vote on directors, auditor, and executive pay matters.SRZN
Proxy filing1 Apr 2026 - Multi-functional antibodies targeting Wnt, VEGF, and IL-6 address major unmet needs in retinal disease.SRZN
Corporate presentation24 Mar 2026 - Biotech firm launches $200M shelf, including $50M ATM with TD Cowen, targeting ophthalmology.SRZN
Registration filing23 Mar 2026 - Cash rose to $89M, net loss widened to $242M, IND for SZN-8141 expected H2 2026.SRZN
Q4 202523 Mar 2026 - Advancing multispecific antibody therapies for retinal diseases, aiming for superior outcomes.SRZN
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - Lead Wnt/VEGF bispecifics advance toward IND in 2026, backed by strong IP and financials.SRZN
Guggenheim Securities Emerging Outlook: Biotech Summit 202612 Feb 2026